Clinical Research Details
Title:
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritede in Subjects with Decompensated Heart Failure (ASCEND-HF)
Purpose:
The primary objective is to evaluate whether treatment with nesiritide improves patient outcomes (as measured by reduction in the composite of heart failure re-hospitalizations and all-cause Mortality through 30 days after randomization or heart failure symptoms (as measured by subject self-assessed Likert dyspnea scale at 6 and 24 hours after study drug initiation) compared with placebo when each is administered in addition to other standard therapies in subjects with acute decompensated heart failure.
Study Number:
200063
Number of Patients:
7000
Elgibility:
18 years or older who are hospitalized for the management of acute decompensated heart failure, or who are diagnosed within 48 hours of hospitalization.
Treatment:
In addition to treatments usually used by doctors to treat your heart failure, by taking part in this study, you will be given nesiritide or placebo as a single (bolus) dose followed by continuous intravenous (IV-into a vein) infusion of nesiritide or placebo for a minimum of 24 hours (1 day) up to a maximum of 168 hours (7 days). Under certain circumstances your doctor may decide to start the infusion without giving you a bolus of study drug. The amount of time that you get study drug will be up to the study doctor.
Principal Investigator:
Enrollment Phone:
(708) 327-2723